ADA and severe combined immunodeficiency: In 1990, gene therapy was first applied clinically in a trial treating two children with Adenosine-deficient Severe Combined Immunodeficiency (ADA-SCID), using retroviral vectors to introduce the ADA gene into their T cells [10].